Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...

Indevus Pharmaceuticals Inc. gained U.S. rights to Nebido, an injectable treatment for hypogonadism developed and previously launched in Europe by Berlin-based Schering AG. Terms call for Indevus to ...

German chemicals giant Bayer said on Thursday it was selling its male testosterone replacement drug Nebido for up to half-a-billion euros in order to concentrate on medical innovation. The Barron's ...

Shares of Indevus Pharmaceuticals Inc. plunged nearly 70 percent after the company reported at least a two-year setback for Nebido, its three-month formulation of testosterone, for male hypogonadism ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ATLANTA — Testosterone undecanoate therapy is associated ...

Please provide your email address to receive an email when new articles are posted on . Testosterone replacement therapy combined with lifestyle modification may contribute to improved metabolic and ...

Endo Pharmaceuticals and Indevus Pharmaceuticals have announced that the FDA has accepted for review their complete response submission to the New Drug Application (NDA) for Nebido (testosterone ...

BERLIN, July 14 (Reuters) - Bayer (BAYGn.DE), opens new tab is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 ...